Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines

被引:0
|
作者
Wilkinson, Thomas [1 ]
Garcia-Prats, Anthony J. [2 ,3 ]
Sachs, Tina [3 ]
Paradkar, Mandar [4 ,5 ]
Suryavanshi, Nishi [4 ,5 ]
Kinikar, Aarti [6 ]
Frias, Melchor V. [7 ]
Sinanovic, Edina [1 ]
Hesseling, Anneke C. [3 ]
Seddon, James. A. [3 ,8 ]
Palmer, Megan [3 ]
机构
[1] Univ Cape Town, Sch Publ Hlth & Family Med, Hlth Econ Unit, Cape Town, South Africa
[2] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA
[3] Stellenbosch Univ, Fac Med & Hlth Sci, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Stellenbosch, South Africa
[4] Johns Hopkins Univ Clin Res Site, Byramjee Jeejeebhoy Govt Med Coll, Pune, Maharashtra, India
[5] Johns Hopkins India, Ctr Infect Dis India, Pune, India
[6] Byramjee Jeejeebhoy Govt Med Coll Sassoon Gen Hos, Dept Paediat, Pune, Maharashtra, India
[7] De La Salle Med & Hlth Sci Inst, Res Div, Dasmarinas City, Cavite, Philippines
[8] Imperial Coll London, Dept Infect Dis, London, England
来源
PLOS ONE | 2024年 / 19卷 / 07期
关键词
REGIMENS; DISEASE;
D O I
10.1371/journal.pone.0305930
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs for prioritisation and budgeting decisions, and an existing knowledge gap at local and international levels. This normative cost analysis was nested in a Phase I/II pharmacokinetics, safety, tolerability, and acceptability trial of TB medications in children in South Africa, the Philippines and India. It assessed the pharmaceutical costs of 36 childhood RR-TB regimens using combinations from 16 different medicines in 34 oral formulations (adult and child-friendly) in 11 weight bands in children <15 years of age. The analysis used local and Global Drug Facility pricing, and local and international guideline recommendations, including adaptions of BPaL and BPaLM regimens in adults. Costs varied significantly between regimen length, age/weight banding, severity of disease, presence of fluroquinolone resistance, and different country guideline recommendations. WHO recommended regimen costs ranged 12-fold: from US$232 per course (short regimen in non-severe disease) to US$2,761 (long regimen in severe, fluroquinolone-resistant disease). Regimen treating fluoroquinolone-resistant infection cost US$1,090 more than comparable WHO-recommended regimen. Providing child-friendly medicine formulations in <5-year-olds across all WHO-recommended regimens is expected to cost an additional $380 (range $212-$563) per child but is expected to have wider benefits including palatability, acceptability, adherence, tolerability, and dose accuracy. There were substantial differences in regimen affordability between countries when adjusted for purchasing power and domestic spending on health. Appropriate, effective, and affordable treatment options are an important component of the fight against childhood RR-TB. A comprehensive understanding of the cost and affordability dynamics of treatment options will enable national TB programs and global collaborations to make the best use of limited healthcare resources for the care of children with RR-TB.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities
    Howell, Pauline
    Achar, Jay
    Huang, G. Khai Lin
    Mariandyshev, Andrei
    Schaaf, H. Simon
    Garcia-Prats, Anthony J.
    PATHOGENS, 2022, 11 (04):
  • [22] Pediatric delamanid treatment for children with rifampicin-resistant TB
    Tyeku, N.
    Apolisi, I.
    Daniels, J.
    Beko, B.
    Memani, B.
    Cengani, L.
    Fatshe, S.
    Gumede, N.
    Joseph, K.
    Mathee, S.
    Furin, J.
    Maugans, C.
    Cox, H.
    Reuter, A.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (10) : 986 - 988
  • [23] Treatment outcomes and safety in children with rifampicin-resistant TB
    Lopez-Varela, E.
    Garcia-Prats, A. J.
    Seddon, J. A.
    Draper, H. R.
    Winckler, J.
    van der Laan, L.
    Palmer, M.
    Burger, W. A.
    Schaaf, H. S.
    Hesseling, A. C.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (02) : 133 - +
  • [24] Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa
    Loveday, Marian
    Hughes, Jennifer
    Sunkari, Babu
    Master, Iqbal
    Hlangu, Sindisiwe
    Reddy, Tarylee
    Chotoo, Sunitha
    Green, Nathan
    Seddon, James A.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (07) : 1158 - 1168
  • [25] Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap
    Nunn, Andrew
    Tweed, Conor
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (10) : 1418 - 1419
  • [26] Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study
    Berhanu, Rebecca
    Schnippel, Kathryn
    Mohr, Erika
    Hirasen, Kamban
    Evans, Denise
    Rosen, Sydney
    Sanne, Ian
    PLOS ONE, 2016, 11 (11):
  • [27] Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success
    Daniels, Johnny Flippie
    Khogali, Mohammed
    Mohr, Erika
    Cox, Vivian
    Moyo, Sizulu
    Edginton, Mary
    Hinderaker, Sven Gudmund
    Meintjes, Graeme
    Hughes, Jennifer
    De Azevedo, Virginia
    van Cutsem, Gilles
    Cox, Helen Suzanne
    PLOS ONE, 2015, 10 (11):
  • [28] Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis
    Brooks, Jordan T.
    Solans, Belen P.
    Beranger, Agathe
    Schaaf, H. Simon
    van der Laan, Louvina
    Sharma, Sangeeta
    Furin, Jennifer
    Draper, Heather R.
    Hesseling, Anneke C.
    Garcia-Prats, Anthony J.
    Savic, Radojka M.
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (06) : 1495 - 1502
  • [29] Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Mullerpattan, Jai Bharat
    Nikam, Chaitali
    Sharma, Ujjwal
    Rodrigues, Camilla
    Pinto, Lancelot Mark
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (01)
  • [30] “A very humiliating illness”: a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa
    Jennifer Furin
    Marian Loveday
    Sindisiwe Hlangu
    Lindy Dickson-Hall
    Sacha le Roux
    Mark Nicol
    Helen Cox
    BMC Public Health, 20